Patients who experience persistent palpitations beyond 8 weeks at a stable dose should undergo formal cardiac evaluation, including ECG and Holter monitoring, to rule out atrial fibrillation or other arrhythmias that GLP-1 therapy may have unmasked rather than caused
Check with your plan administrator to confirm coverage
Necrotizing fasciitis of the perineum may lead to hospitalization, may require multiple surgeries, and may lead to death
2024 Dec 31:111368
Key Observations from Phase 2 Data Dose escalation reduced adverse events: Groups that used gradual dose titration reported fewer GI events than those starting at the target dose directly No deaths were attributed to the study drug Serious adverse events were reported at low rates across all groups, with no clear dose-dependent pattern for serious events The placebo group also reported substantial adverse events (72.1%), which is typical for trials of this size and duration TRIUMPH Phase 3 Adverse Event Profiles The TRIUMPH program consists of eight Phase 3 trials evaluating retatrutide across multiple indications including obesity, type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD)
The Bottom Line Choosing between glutathione and an NAD+ Booster depends on your primary health needs